The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is evaluating the efficacy and safety of a single ...

Future research will show whether the change in the availability of hallucinogens affects the risks associated with these ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Life Sciences (ATAI) announced the completion of patient enrollment in the eight-week, double-blind, core stage of the global Phase 2b ...

Ketamine is often viewed more as a party drug than a medicine. One Columbia clinic is using the drug to help patients with ...

Psychedelics have been recreational substances for decades. Now, they're entering the mainstream of psychiatric treatment.

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...

"We were in Elko and couldn't find treatment — even to travel, we couldn't find treatment and the wait lists were long. Availability was really scarce. It was very discouraging," ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...

The global depression treatment market, valued at USD 11 billion in 2024, is poised for steady growth, projected to reach USD 18.3 billion by 2034 at a CAGR of 5.2%. This expansion is driven by ...

St John of God Hospital in Dublin has said it is the first hospital in Ireland to introduce a special treatment for patients ...